Two years after Astellas hit the market with a nonhormonal therapy for menopause, Bayer has followed suit, scoring its first worldwide nod for a similar hormone-free treatment. The U.K.’s Medicines ...
In 2025, menopause care has entered a new era, with groundbreaking drugs, refined hormone guidelines, and science-backed mind–body therapies transforming how women find relief. October’s World ...
FiercePharma: Bayer scores first approval for hormone-free menopause drug Lynkuet in UK
For decades, menopause was treated as a taboo topic, spoken about in private and viewed as a sign of decline rather than a natural stage of life. Today, women, including celebrities and other ...
Prefer Newsweek on Google to see more of our trusted coverage when you search. Women will soon be able to access menopause treatment, alongside prescriptions for hair growth, weight loss, birth ...
Nasdaq: Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
This approval is supported by data from the Phase III OASIS clinical trial program evaluating Lynkuet for the treatment of moderate to severe hot flashes due to menopause1 In OASIS 1 and OASIS 2, ...
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
Medical Xpress: Thinking about acupuncture or herbs for menopause? Read this first
Yahoo: 95% of women in menopause aren't offered treatment: Here’s how to get needed care